Skip to main content

Vivos Therapeutics, Inc.

VVOS
Exchange
Nasdaq
Industry
Surgical & Medical Instruments & Apparatus
SEC CIK
0001716166

No open-market purchases or sales by Vivos Therapeutics, Inc. insiders were filed in the last 90 days; 22 institutions reported holding it in 13F filings for Q2 2026, worth $242.7K in total; no superinvestor holds it.

Q2 2022 vs. Q1 2022

How the institutions holding Vivos Therapeutics, Inc. changed between Q1 2022 and Q2 2022.

All holders in Q2 2022All holders in Q1 2022

13F holders of VVOS: Q1 2022 compared with Q2 2022
MeasureQ1 2022Q2 2022Change
Holders28280
Shares2.49M2.18M−304.8K (−12.3%)
Value$6.66M$2.82M−$3.84M (−57.7%)

New holders (5)

Institutions that held Vivos Therapeutics, Inc. at the end of Q2 2022 but not at the end of Q1 2022.

Institutions new to VVOS in Q2 2022
InstitutionSharesValue% of portfolio
Virtu Financial LLC11,805$15.0K0.00%
Ronald Blue Trust, Inc.4,000$11.0K0.00%
UBS Group AG2,213$3.00K0.00%
Wagner Wealth Management, LLC2,000$3.00K0.00%
FMR LLC1$00.00%

Sold out (5)

Institutions that held Vivos Therapeutics, Inc. at the end of Q1 2022 and filed for Q2 2022 without it.

Institutions that sold out of VVOS in Q2 2022
InstitutionShares, Q1 2022Value, Q1 2022
Point72 Asset Management, L.P.170,264$456.0K
Griffin Asset Management, Inc.70,200$188.0K
Susquehanna International Group, LLP23,740$64.0K
Millennium Management LLC11,244$30.0K
IFP Advisors, Inc150$1.00K